86 results
Page 2 of 5
6-K
EX-99.1
x55ol8dj
3 Oct 22
Galapagos receives positive CHMP opinion for Jyseleca® European label update based on testicular function safety data from MANTA/RAy studies
6:02pm
6-K
EX-99.2
ozn817eftsrc
8 Aug 22
First key steps in pipeline rebuild and strong commercial progress in H1 2022
4:59pm
6-K
EX-99.1
5uqefnwph2mpvne
8 Aug 22
First key steps in pipeline rebuild and strong commercial progress in H1 2022
4:59pm
6-K
EX-99.2
3exhms7gh jzwm1
6 May 22
Current report (foreign)
5:18pm
6-K
EX-99.1
73127
24 Feb 22
Galapagos 2021 results set stage for future growth
5:19pm
6-K
EX-99.1
qsayp42arwoq01 vfcxq
7 Feb 22
Current report (foreign)
2:40pm
6-K
EX-99.2
wega pjxs
8 Nov 21
Galapagos reports commercial and operational progress at Q3 financial results
4:03pm
6-K
EX-99.1
4mpu7 tx82
6 Oct 21
Galapagos presents new data from the SELECTION Phase 3 program at the United European Gastroenterology Week (UEGW) 2021 congress
6:00am
6-K
EX-99.1
gz34x303ay
6 Oct 21
Galapagos announces completion of patient enrollment for DIVERSITY Phase 3 study with filgotinib in Crohn’s Disease
6:00am
6-K
EX-99.2
jcsjq1s
5 Aug 21
Galapagos reports H1 financial results with refocused pipeline and operational progress
4:02pm
6-K
EX-99.1
ud0hvchbns
5 Aug 21
Galapagos reports H1 financial results with refocused pipeline and operational progress
4:02pm
6-K
EX-99.1
qcx42 5yqhdndnzq4r
14 Jul 21
Current report (foreign)
5:27pm
6-K
EX-99.1
fr6046s1j
14 Jul 21
Galapagos reports positive topline results with selective TYK2 inhibitor GLPG3667 in Phase 1b psoriasis study
5:13pm
6-K
EX-99.1
qeh27x
12 Jul 21
New post-hoc analyses of data from SELECTION Phase 3 program presented at European Crohn’s and Colitis Organisation (ECCO) virtual congress
9:02am
6-K
EX-99.3
up5yg0f29g
11 May 21
Current report (foreign)
2:10pm
6-K
EX-99.2
p6qrj121felmpbl
11 May 21
Current report (foreign)
2:10pm
6-K
EX-99.1
c1we27348p2d2q3
15 Dec 20
Current report (foreign)
4:55pm
6-K
EX-99.2
6umr6px9lt ys78bxg
9 Nov 20
Galapagos reports Q3 2020 results
4:01pm